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Abstract
Background
We demonstrated in experimental studies that hypercholesterolaemia enhances the prolif-
eration of haematopoietic stem cells and the subsequent differentiation to neutrophils,
whereas HDL-cholesterol inhibits these processes. To translate our experimental findings
to clinical practice, we investigated in Chinese type-2 diabetic patients and in Flemish non-
diabetic people the independent and joint associations of insulin resistance with markers of
dyslipidaemia and inflammation, while looking for consistency between ethnicities and
across the spectrum of insulin resistance.
Methods
We studied 798 Chinese patients with type-2 diabetes (53.6% women; mean age, 60.6
years) admitted to a tertiary referral centre and 1060 white Flemish (50.5%; 51.1 years) ran-
domly recruited in Northern Belgium. Fasting insulin resistance (HOMA-IR) was derived
from C-peptide in Chinese and from insulin in Flemish using the Homeostasis Model of
Assessment algorithm. In multivariable-adjusted analyses, HOMA-IR was regressed on tri-
glycerides, HDL-cholesterol and neutrophil count.
Results
In Chinese patients, the percentage changes in HOMA-IR associated with triglycerides,
HDL-cholesterol and neutrophils (per 1-SD increment) amounted to 8.1 (95% confidence
interval, 3.0 to 13.4; p = 0.0015), -8.7 (-13.0 to -4.2; p = 0.0002) and 5.6 (1.0 to 10.4; p =
0.017). In non-diabetic Flemish, the corresponding estimates were 11.7 (8.3 to 15.1;
p<0.0001), -1.7 (-4.6 to 1.4; p = 0.28) and 3.3% (0.5 to 6.3; p = 0.022), respectively. None of
the interaction terms between the three explanatory variables reached significance in Chi-
nese or Flemish (p0.10).
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Conclusions
Insulin resistance increases with the serum level of triglycerides and the blood neutrophil
count, but decreases with serum HDL-cholesterol concentration. These associations were
consistent in Chinese type-2 diabetic patients and non-diabetic Flemish people and were
independent from one another. The clinical implications are that future studies should focus
on intervening with serum triglyceride and HDL-cholesterol levels or controlling inflamma-
tion as a way to prevent or treat insulin resistance.
Introduction
Insulin resistance refers to the deficient regulation by insulin of energy substrate utilisation in
peripheral tissues. It is a major risk factor in the pathogenesis of type-2 diabetes mellitus.[1]
Insulin resistance is characterised by dyslipidaemia, as exemplified by high triglyceride levels
and low concentration of high-density lipoprotein (HDL) cholesterol, the most likely underly-
ing cause being the increased free fatty acid flux secondary to insulin resistance.[1] Further-
more, experimental research[2, 3] and human studies[4] established that inflammatory
processes either contribute to insulin resistance, in particular in the presence of obesity, or
evolve as a consequence of the metabolic dysregulation associated with insulin resistance.[5] In
keeping with the literature,[2, 3, 5] we recently demonstrated in experimental studies[6] that
hypercholesterolaemia enhances the proliferation of haematopoietic stem cells and their subse-
quent differentiation to neutrophils, whereas HDL-cholesterol inhibits these processes. These
findings support the role of low-grade inflammation as a pathogenetic mechanism in diabetes
mellitus and its complications.[7]
Previous clinical studies of the association of insulin resistance with markers of inflamma-
tion[7–10] or dyslipidaemia included middle-aged overweight or obese participants,[11–13]
people at risk of diabetes mellitus,[9–11] or patients with the metabolic syndrome[11–13] or
type-2 diabetes.[14, 15] These studies were small[15] or confined to selected volunteers[13] or
to a specific ethnic group.[8] To dissect the independent associations of insulin resistance with
markers of dyslipidaemia and inflammation and to translate our experimental findings,[6] we
studied insulin resistance in relation to serum triglycerides and HDL-cholesterol and the blood
neutrophil count in Chinese patients with type-2 diabetes mellitus and in non-diabetic people
randomly recruited from a Flemish population.
Methods
Study populations
The Chinese and Flemish studies complied with the Helsinki Declaration for investigation of
human subjects. They received ethical approval from the competent Institutional Review
Boards of the Capital Medical University and the Faculty of Medicine of the University of Leu-
ven. All participants provided written informed consent.
From 2006 until 2011, 1054 diabetic patients were admitted to the Department of Endocri-
nology at Lu He hospital in Beijing. According to the diagnostic criteria of the American Diabe-
tes Association, 946 had type-2 diabetes and were eligible for analysis. They all had a plasma
glucose of at least 7.0 mmol/L while fasting or of 11.0 mmol/L or more 2 hours after an orally
administered glucose load of 75 gram. We excluded 148 patients from analysis, because not all
required measurements were available on the database (n = 117) or because of extreme values
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of variables exceeding the mean by 3 SDs or more (n = 31). Thus the number of Chinese dia-
betic patients statistically analysed totalled 798. Recruitment for the Flemish Study on Environ-
ment, Genes and Health Outcomes (FLEMENGHO) started in 1985 and continued until 2004.
[16] The initial participation rate was 78.0%. The participants were repeatedly followed up.
FromMay 2005 until June 2014, we mailed an invitation letter to 2115 former participants for
a follow-up examination. However, 303 were unavailable, because they had died (n = 70),
because they had been institutionalised or were too ill (n = 60), or because they had moved out
of the area (n = 173). Of the remaining 1812 former participants, 1352 renewed informed con-
sent. The participation rate was therefore 74.6%. We excluded 292 participants from analysis,
because they had diabetes (n = 49) defined as a fasting plasma glucose of 7.0 mmol/L or higher,
because fasting insulin or glucose were not available in the database (n = 231), or because mea-
surements deviated more than 3 SDs from the mean (n = 12). The analyses therefore included
1060 non-diabetic FLEMENGHO participants (S1 Fig).
Clinical measurements
In both studies, trained observers measured blood pressure to the nearest 2 mm Hg by auscul-
tation of the Korotkoff sounds, using a standard mercury sphygmomanometer. Blood pressure
was the average of three readings in Lu He patients and five in FLEMENGHO participants.
Mean arterial pressure was diastolic pressure plus one third of pulse pressure. Hypertension
was a blood pressure of at least 140 mmHg systolic or 90 mmHg diastolic or use of antihyper-
tensive drugs. The observers measured each participant’s anthropometric characteristics and
collected information on medical history, smoking and drinking habits, and intake of medica-
tions, using structured interviews in Lu He patients or standardised questionnaires in FLE-
MENGHO. Body mass index was weight in kilograms divided by the square of height in
meters.
Biochemical measurements
With participants fasting, venous blood samples were drawn for measurement of the total and
differential white blood cell count, serum total cholesterol, high-density lipoprotein (HDL)
cholesterol, triglycerides, and creatinine, plasma glucose, and serum levels of C-peptide or
insulin. Insulin resistance was computed by Homeostasis Model Assessment (HOMA-IR;
http://www.dtu.ox.ac.uk/HOMAcalculator/), using C-peptide in diabetic patients and insulin
in non-diabetic people. Glomerular filtration rate (eGFR) was derived from serum creatinine
by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.[17] Low-
density lipoprotein (LDL) cholesterol was computed from serum total and HDL-cholesterol
and serum triglycerides by the Friedewald equation.[18] Participants were classified as having
dyslipidaemia if at least one of the following criteria was met: total cholesterol higher than 4.9
mmol/L, LDL-cholesterol exceeding 3 mmol/L, triglycerides higher than 1.7 mmol/L or HDL-
cholesterol less than 1.2 mmol/L in women and 1 mmol/L in men.[19]
Statistical analysis
For database management and statistical analysis, we used the SAS system, version 9.3 (SAS
Institute Inc., Cary, NC). Significance was a two-tailed α-level of 0.05 or less. We normalised
the distributions of HOMA-IR, C-peptide and insulin by a logarithmic transformation. For
untransformed and logarithmically transformed variables, we expressed the central tendency
and spread of the distributions by the arithmetic mean and SD and the geometric mean and
interquartile range, respectively. We compared means by the large-sample z-test and propor-
tions by Fisher’s exact test. In unadjusted analyses, we explored trends of variables across thirds
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of the distributions of HOMA-IR, C-peptide and insulin. We searched for covariables of the
indexes of insulin resistance using a stepwise regression procedure with the p-values for vari-
ables to enter and stay in the models set at 0.15. The covariables considered were sex, age, body
mass index, mean arterial pressure, use of antidiabetic drugs (insulin, sulphonylurea, metfor-
min and α-glucosidase inhibitors), lipid-lowering drugs (statins, niacin and fibrates), antihy-
pertensive drugs (diuretics, β-blockers, calcium-channel blockers and inhibitors of the renin-
angiotensin system [angiotensin-converting enzyme inhibitors and angiotensin receptor block-
ers]) and nonsteroidal anti-inflammatory drugs including aspirin. We standardised the indexes
of insulin resistance to the average in the population (mean or ratio) of significant covariables
identified by stepwise regression. While accounting for covariables by standardisation, we
regressed the indexes on insulin resistance on serum triglycerides and HDL-cholesterol and the
neutrophil count, first considering each of these three variables separately and next introducing
all three together in the same model. Finally, we searched for interaction between these three
variables.
Results
Characteristics of participants
In all 798 Lu He patients (53.4% women), age averaged (SD) 60.6 (12.9) years, body mass index
25.6 (3.6) kg/m2, and blood pressure 134.9 (20.7) mm Hg systolic and 80.4 (20.7) mm Hg dia-
stolic. Mean values were 1.75 (1.15) mmol/L for triglycerides, 4.70 (1.08) and 1.08 (0.28) for
total and HDL-cholesterol, respectively, and 97.3 (26.0) mL/min/1.73 m2 for eGFR. Geometric
means were 1.03 (IQR, 0.69–1.58) for HOMA-IR and 0.40 nmol/L (IQR, 0.26–0.62) for C-pep-
tide. Of the 798 diabetic patients, 605 (75.8%) had dyslipidaemia and 428 (53.6%) had hyper-
tension. In all 1060 FLEMENGHO participants (50.6% women), age averaged 51.1 (15.6)
years, body mass index 26.2 (4.2) kg/m2, and blood pressure 130.2 (17.0) mm Hg systolic and
80.8 (9.5) mm Hg diastolic. Mean values were 1.62 (0.88) mmol/L for triglycerides, 5.10 (0.93)
and 1.48 (0.38) for total and HDL-cholesterol, respectively, and 86.1 (23.6) mL/min/1.73 m2
for eGFR. Geometric means were 0.64 (IQR, 0.40–0.95) for HOMA-IR and 34.5 pmol/L (IQR,
21.5–50.9) for insulin. Of the 1060 non-diabetic participants, 747 (70.5%) had dyslipidaemia
and 331 (31.2%) had hypertension. S1 Table describes the use of drugs for diabetes, dyslipidae-
mia and hypertension by drug class in the two study populations.
Unadjusted analyses
We explored trends in the main variables across thirds of the distribution of the indexes of
insulin resistance. In Lu He patients, the prevalence of dyslipidaemia (p = 0.0001), hyperten-
sion (p = 0.0027), history of cardiovascular disease (p = 0.0304) and renal dysfunction
(p = 0.0002) increased with higher HOMA-IR category (Table 1). Body mass index
(p<0.0001), diastolic blood pressure (p = 0.0053), serum triglycerides (p<0.0001) and both the
white blood cell (p = 0.0014) and neutrophil counts (p = 0.030) increased with higher
HOMA-IR, whereas HDL-cholesterol showed the opposite trend (p<0.0001). Among Flemish
people, the prevalence of dyslipidaemia (p<0.0001), hypertension (p = 0.0011) and renal dys-
function (p = 0.0125) increased across thirds of the HOMA-IR distribution (Table 1). Body
mass index, (p<0.0001), systolic blood pressure (p<0.0001), serum triglycerides (p<0.0001)
and the neutrophil count (p = 0.019) increased with higher HOMA-IR, whereas HDL-choles-
terol showed the opposite trend (p<0.0001). Analyses across thirds of the C-peptide distribu-
tion in Chinese diabetic patients and across thirds of the insulin distribution in non-diabetic
Flemish produced results similar to those associated with HOMA-IR computed from these var-
iables (S2 Table and Fig 1).
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Multivariable-adjusted analyses
S3 Table list the covariables selected by stepwise regression to be accounted for in the multi-
variable adjusted analyses. For continuous variables association sizes were standardised to a
1-SD increment in the explanatory variable. In Lu He patients, HOMA-IR increased with body
mass index (effect size, +27.1%; p<0.0001) and mean arterial pressure (+5.9%; p = 0.018).
HOMA-IR was also positively and independently associated with use of niacin (+16.8%;
Table 1. Characteristics of diabetic patients and non-diabetic people by category of insulin resistance.
Characteristic Type-2 diabetic Lu He patients Non-diabetic FLEMENGHO participants
Category of insulin resistance Category of insulin resistance
Limits <0.81 0.81–1.42 >1.42 <0.49 0.49–0.81 >0.81
N° in category (%) 265 267 266 352 355 353
Women 151 (57.0%) 147 (55.1%) 128 (48.1%) 194 (55.1%) 176 (49.6%) 166 (47.0%)
Hypertension 122 (46.0%) 144 (53.9%) 162 (60.9%) 90 (25.6%) 106 (30.0%) 135 (38.2%)*
Dyslipidaemia 179 (67.5%) 204 (76.4%)* 222 (83.5%)* 222 (63.1%) 243 (68.5%) 282 (79.9%)ǂ
Previous cardiovascular
disease
45 (17.0%) 49 (18.4%) 68 (25.6%)* 25 (7.1%) 34 (9.6%) 34 (9.6%)
eGFR < 60 mL/min/1.73 m2 17 (6.4%) 18 (6.7%) 42 (15.8%)ǂ 37 (10.5%) 60 (16.9%)* 63 (17.9%)
Mean (SD)
Age (years) 61.2 (12.9) 61.1 (11.9) 59.4 (13.) 49.6 (14.5) 51.54 (15.6) 52.3 (16.6)
Body mass index (kg/m2) 23.9 (3.3) 25.9 (3.3)§ 26.9 (3.7)ɫ 23.9 (3.0) 26.0 (3.6)§ 28.8 (4.2)§
Systolic pressure (mm Hg) 134.2 (22.7) 134.4 (17.9) 136.0 (21.3) 127.5 (16.6) 130.1 (17.6)* 133.0 (16.5)*
Diastolic pressure (mm Hg) 78.8 (11.6) 80.4 (10.7) 82.1 (10.9)* 79.5 (9.4) 80.5 (9.3) 82.5 (9.6)ɫ
Heart rate (beats per minute) 79.2 (10.3) 78.3 (12.1) 79.1 (11.0) 61.5 (8.6) 63.0 (8.9)* 65.6 (9.9)ǂ
Plasma glucose (mmol/L) 7.6 (2.7) 8.3 (3.0)ɫ 9.2 (3.4)ɫ 4.6 (0.4) 4.7 (0.4)ǂ 4.9 (0.6)ǂ
eGFR (mL/min/1.73 m2) 100.1 (22.3) 98.5(25.3) 93.1 (29.4)* 88.9 (21.1) 86.1 (24.7) 83.3 (24.6)*
Total cholesterol (mmol/L) 4.76 (1.06) 4.61 (1.04) 4.78 (1.14) 5.10 (0.90) 5.03 (0.91) 5.16 (0.98)
HDL cholesterol (mmol/L) 1.17 (0.28) 1.07 (0.26)§ 0.99 (0.27)ǂ 1.62 (0.39) 1.46 (0.36)§ 1.35 (0.35)§
LDL cholesterol (mmol/L) 2.98 (0.93) 2.84 (0.88) 2.96 (0.97) 2.92 (0.76) 2.87 (0.80) 2.87 (0.85)
Triglycerides (mmol/L) 1.33 (0.78) 1.71 (1.03)§ 2.19 (1.38)§ 1.25 (0.52) 1.55 (0.77)§ 2.06 (1.05)§
White blood cell count (× 109/L) 6.4 (1.6) 6.7 (1.7)* 6.9 (1.7) 6.3 (1.6) 6.3 (1.6) 6.5 (1.7)*
Neutrophils (%) 60.4 (10.1) 59.5 (10.1) 60.6 (9.4) 56.9 (7.7) 58.2 (7.9)* 58.1 (8.4)
Geometric mean (IQR)
C-peptide (nmol/L) 0.19 (0.16–
0.28)
0.42 (0.36–
0.50)§
0.79 (0.61–
0.96)§
. . . . . . . . .
Insulin (pmol/L) . . . . . . . . . 18.3 (14.4–
21.5)
33.7 (28.7–
37.3)§
66.2 (50.9–
78.2)§
Abbreviations: eGFR, estimated glomerular filtration rate derived from serum creatinine by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation; HDL, high-density lipoprotein; LDL, low-density lipoprotein; IQR interquartile range. Insulin resistance was computed by Homeostasis Model
Assessment algorithm (http://www. dtu.ox.ac.uk/HOMAcalculator/) using C-peptide in diabetic patients and insulin in non-diabetic people. Hypertension
was a blood pressure of 140 mm Hg systolic or 90 mm Hg diastolic or use of antihypertensive drugs. Dyslipidaemia included total cholesterol >4.9
mmol/L, LDL-cholesterol >3 mmol/L, or triglycerides >1.7 mmol/L or HDL-cholesterol <1.2 mmol/L in women and <1 mmol/L in men. Significance of the
difference with the adjacent lower third
* p0.05
ɫ p0.01
ǂ p0.001
§ p0.0001
An ellipsis indicates variable not measured.
doi:10.1371/journal.pone.0153171.t001
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Fig 1. Serum triglycerides (A, D), serumHDL-cholesterol (B, E) and neutrophil count (C, F) by thirds of the distribution of insulin resistance. Insulin
resistance was computed by Homeostasis Model Assessment algorithm (HOMA-IR), using C peptide in diabetic Lu Hepatients (A, B, C) patients and insulin
in non-diabetic FLEMENGHO participants (D, E, F). Significance of the difference with the adjacent lower third: ɫ p0.01; § p0.0001.
doi:10.1371/journal.pone.0153171.g001
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p = 0.039) and inversely with insulin treatment (-23.0%; p<0.0001). Use of β-blockers was
weakly associated with HOMA-IR (+14.0%; p = 0.10). Together, these covariables explained
17.9% of the variance in the Chinese diabetic patients. In Flemish, HOMA-IR decreased with
age (-6.6%; p<0.0001) but increased with body mass index (+35.8%; p<0.0001), use of statins
(+16.1%; p = 0.0013), use of fibrates (+53.0%; p = 0.014) and use of β-blockers (+14.3%;
p = 0.006). The independent and positive associations in Flemish of HOMA-IR with use of
nonsteroidal anti-inflammatory drugs (+9.1%; p = 0.067) did not reach formal significance.
Combined, these covariables explained 30.4% of the HOMA-IR variance in the non-diabetic
Flemish.
In the next step of the analysis, we standardised HOMA-IR to the average (mean or ratio) of
the aforementioned covariables identified by stepwise regression in the two study populations.
Triglycerides, HDL-cholesterol and neutrophil count were first entered separately in the mod-
els (Table 2). In Chinese diabetic patients, HOMA-IR was positively associated with triglycer-
ides and neutrophil count and inversely with HDL-cholesterol. Per 1-SD increment in the
explanatory variable, the changes in HOMA-IR amounted to +11.7% (p<0.0001), +5.8%
(p = 0.017) and -11.2% (p<0.0001). In Flemish non-diabetic participants, the corresponding
estimates were +12.8% (p<0.0001), +3.8% (p = 0.0125) and -6.2% (p<0.0001), respectively.
Models relating HOMA-IR to the three explanatory variables jointly produced similar results,
although in Flemish participants the association between HOMA-IR and HDL-cholesterol
weakened to -1.7% (p = 0.28). None of the interaction terms between the three explanatory var-
iables reached significance in Chinese (p0.10) or Flemish (p0.10).
Analyses, in which HOMA-IR was substituted by C-peptide in Lu He patients or by insulin
in Flemish, produced consistent results both in terms of selection of covariables for which the
insulin indexes had to be standardised (S3 Table) as in terms of the associations with triglycer-
ides, HDL-cholesterol or neutrophil count (Table 2 and Figs 2 and 3).
Discussion
The key finding of the current study was that insulin resistance, as captured by the HOMA-IR
index, increased with the serum level of triglycerides and the blood neutrophil count and
decreased with serum HDL-cholesterol. These associations were independent of one another
Table 2. Multivariable-adjusted associations of insulin resistance with serum lipids and neutrophil count.
Population Explanatory variable HOMA-IR Insulin index
Estimate (95% CI) p Estimate (95% CI) p
Lu He patients
Triglycerides (+1.15 mmol/L) 11.7 (6.8 to 16.9) <0.0001 8.0 (3.4 to 12.9) 0.0006
HDL-cholesterol (+0.28 mmol/L) -11.2 (-15.1 to -7.1) <0.0001 -8.6 (-12.5 to -4.5) <0.0001
Neutrophils (1.41 × 109/L) 5.8 (1.0 to 10.7) 0.017 5.6 (1.1 to 10.4) 0.0151
FLEMENGHO participants
Triglycerides (+0.88 mmol/L) 12.8 (9.4 to 15.8) <0.0001 12.4 (9.3 to 15.7) <0.0001
HDL-cholesterol (+0.38 mmol/L) -6.0 (-8.7 to -3.3) <0.0001 -5.8 (-8.5 to -3.1) <0.0001
Neutrophils (1.21 × 109/L) 3.8 (0.9 to 6.9) 0.0112 4.0 (1.1 to 7.1) 0.0074
Insulin index refers to C-peptide in Lu He patients and insulin in FLEMENGHO participants. Estimates express the percentage change in the dependent
variable associated with a 1-SD increment in the explanatory variables. All estimates were standardised to the average in each population (mean or ratio)
of age, body mass index, mean arterial pressure, and use of antidiabetic medications (by class), lipid-lowering drugs (by class), antihypertensive drugs (by
class), and nonsteroidal anti-inflammatory drugs (see S3 Table). Each explanatory variable was entered separately in the models.
doi:10.1371/journal.pone.0153171.t002
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and consistent in Flemish and Chinese thereby spanning two ethnic groups and establishing a
continuum ranging from a non-diabetic population sample to type-2 diabetic patients admit-
ted to a tertiary referral hospital.
The idea to move to clinical studies in humans originated from our previous experiments in
mice showing that hypercholesterolaemia induced by a high-fat diet enhanced proliferation of
haematopoietic stem and progenitor cells (HSPC) and their subsequent differentiation to mye-
loid cells including neutrophils.[6] Furthermore, in HSPC isolated from mice and brought into
culture, HDL-cholesterol inhibited differentiation to neutrophils but not to monocytes.[6]
Other researchers demonstrated that higher HDL particle concentrations or HDL functionality
promotes insulin secretion and pancreatic β cell survival, peripheral glucose uptake, and sup-
presses inflammation.[20] Moreover, there is a close link between lipoprotein metabolism,
HDL-cholesterol and circulating levels of triglycerides, which is disturbed in diabetic patients
or in the presence of insulin resistance.[20] Our experimental data explain why we investigated
insulin resistance in relation to serum triglycerides and HDL-cholesterol and why we used neu-
trophil count as an index of inflammation. Several other investigators also proposed total or
neutrophil white blood cell count as a marker of inflammation in diabetic patients, because
these counts predict macro- and micro-vascular complications over and beyond classical risk
factors.[21, 22]
With insulin resistance as outcome, our observational cross-sectional data cannot differenti-
ate whether dyslipidaemia and inflammation are on a causal pathway to insulin resistance or
develop as a consequence of insulin resistance. However, as reviewed elsewhere,[22] experi-
mental evidence clearly demonstrates that under defined conditions inflammatory mediators
alone can trigger insulin resistance in cells, experimental models and humans, suggesting that
inflammation might be proximal to metabolic deterioration.[7] Furthermore, in the presence
of excess of nutrients and energy substrate, metabolic signals likely activate inflammatory path-
ways, which then further disrupt metabolic function, leading to a vicious cycle involving fur-
ther metabolic stress and inflammation.[22] Because we replicated our findings in non-diabetic
people, we propose that in our current study dyslipidaemia and inflammation were chaperones
Fig 2. Insulin resistance (A) and C-peptide or fasting insulin (B) in relation to serum lipids and neutrophil count in Lu He patients and
FLEMENGHO participants. Insulin resistance was computed by Homeostasis Model Assessment algorithm (HOMA-IR), using C peptide in diabetic Lu He
patients (■) and fasting insulin (●) in non-diabetic FLEMENGHO participants. Estimates express the percentage change in the dependent variable
associated with a 1-SD increment in the explanatory variables. All estimates were standardised to the average in each population (mean or ratio) of age,
body mass index, mean arterial pressure, and use of antidiabetic medications (by class), lipid-lowering drugs (by class), antihypertensive drugs (by class),
and nonsteroidal anti-inflammatory drugs (see S3 Table). The three explanatory variables were jointly entered in the models.
doi:10.1371/journal.pone.0153171.g002
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proximal rather than secondary to insulin resistance. Our experimental studies[6] also support
the hypothesis that high serum HDL-cholesterol is proximal to low insulin resistance.
The current study must be interpreted within the context of some potential limitations.
First, as mentioned before, we cannot differentiate the association of insulin resistance with
serum triglycerides and HDL-cholesterol or blood neutrophil count as cause or consequence.
Second, we did not compare the enzymatic activity of circulating neutrophils in participants
with low vs. high insulin resistance. Third, HDL functionality is exerted by the content of the
lipoprotein particles, such as apolipoproteins,[23] enzymes,[23] or microRNAs.[24] Our epide-
miological findings did not address how variation in the content of HDL-particles is related to
insulin resistance. Finally, we only studied blood neutrophil count as established[9] marker of
inflammation. To be addressed, to keep the head to head comparison, the classical CKD-EPI
formula was applied to calculate eGFR in both cohorts. Alternatively, the classical modification
of the CKD-EPI formula for Asian people could be more suitable for Chinese patients. Consis-
tent with previous reports[25, 26], we observed in multivariable regression models higher val-
ues of HOMA-IR in Flemish participants taking statins or in Chinese patients taking niacin
compared with those not receiving statin or niacin therapy.
Fig 3. Insulin resistance as function of the serum levels of triglycerides and HDL-cholesterol and the neutrophil blood cell count. Insulin resistance
was computed by Homeostasis Model Assessment algorithm (HOMA-IR) and plotted along the vertical axis. Serum triglycerides and HDL-cholesterol are
plotted along the horizontal axes. The colour gradient in the modelled two-dimensional plane represent the gradient of the neutrophil blood cell count. All
estimates were standardised to the average in each population (mean or ratio) of age, body mass index, mean arterial pressure, and use of antidiabetic
medications (by class), lipid-lowering drugs (by class), antihypertensive drugs (by class), and nonsteroidal anti-inflammatory drugs (see S3 Table).
doi:10.1371/journal.pone.0153171.g003
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The clinical implication of our study is that lowering serum triglycerides, increasing serum
HDL-cholesterol and controlling inflammation might be important targets in the prevention
or treatment of insulin resistance and its progression to type-2 diabetes mellitus. Intervention
trials focused on controlling the inflammatory activity of monocytes in the treatment of diabe-
tes.[27, 28] In type-2 diabetic patients, interleukin-1β receptor antagonists[27] and neutralising
interleukin-1β antibodies[28] enhance C-peptide secretion[27] and reduce circulating levels of
interleukin-6[27, 28] and C-reactive protein[27, 28], but have no effect on insulin resistance.
[27] The null effect of interleukin-1β suppression on insulin resistance might be explained by
the heterogeneity of macrophage subpopulations that exert opposite effects on insulin resis-
tance[5] and the involvement of other cell types.[29, 30] Recently, experimental data described
the role of neutrophils, T cells and monocytes in the peripheral organs of obese and diabetic
mice.[30–32] Furthermore, in obese mice, deletion of myeloperoxidase or elastase in neutro-
phils prevented insulin receptor substrate 1 degradation and ameliorated pro-inflammatory
cytokine production, resulting in the restoration of insulin signalling pathways, inhibition of
monocyte infiltration of the liver and adipose tissues, and thus improved insulin sensitivity.
[30–32] In line with these experimental mice studies, increased levels of elastase, myeloperoxi-
dase and neutrophil count have also been observed in sera of obese human subjects.[31, 33]
Therefore, controlling neutrophil count and recruitment of neutrophils could be an attractive
target in the prevention and treatment of insulin resistance.
Conclusions
In conclusion, our data demonstrated independent and positive associations of insulin resis-
tance, as measured by HOMA-IR index with serum triglycerides and the blood neutrophil
count, and an inverse association with serum HDL-cholesterol in both non-diabetic FLEMEN-
GHO participants and Chinese type-2 diabetic patients. Our results were consistent across two
ethnic groups and covered the continuum ranging from a non-diabetic population to type-2
diabetic patients. Building on our experimental studies,[6] our observations in humans suggest
that lowering serum triglycerides, increasing serum HDL-cholesterol and controlling inflam-
mation are potential targets for the prevention and treatment of insulin resistance, which
might be universally and cumulatively applicable.
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